score

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Paribus. The Benefits of Collaboration.

After discovering we were victims of an exploit, we’ve decided to share our plans to open-source our code and make it accessible to external developers. Our aims in so doing are simple; through leveraging a wider pool of minds, we will be better positioned to avoid potential faults and bugs that may arise in the future. Open-sourcing code has become increasingly popular in recent years, with many companies and organizations embracing these principles as a way to enhance innovation, reduce costs, and improve transparency. It involves allowing the public to

Paribus Mainnet Countdown.

We know the past few months have been drawn out for everyone eagerly awaiting the release date of our mainnet. Throughout each step, we’ve been direct and transparent with our community, and sometimes maybe a little too hopeful. But now the wait is over. Our developers have been working especially hard to meet the exacting requirements of the Hacken audit and we’re over the moon to have achieved a score of 8.7/10 which we feel represents the hard work of everyone involved. Now that we’ve passed with a high score